The SEC filings page for Ping An Biomedical Co., Ltd. (NASDAQ: PASW) provides access to the company’s U.S. regulatory disclosures as they become available through the EDGAR system. Ping An Biomedical describes itself as a one-stop SCM service provider in the apparel industry and also as a company focused on healthcare and biomedical technology, and its filings are the primary source for detailed information on these activities.
Through this page, investors can review key filing types when they are submitted, such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically discuss business segments, risk factors, and management’s analysis of operations. Current reports on Form 8-K, when filed, can disclose material events such as strategic investment memoranda, share purchase agreements, or notices related to listing standards.
Ping An Biomedical has publicly reported receiving a Nasdaq minimum bid price deficiency letter, and any related developments may also appear in its SEC filings. In addition, ownership and insider activity, when reported on Form 3, 4, or 5, can be accessed from this page to understand changes in shareholdings of directors, officers, or significant holders.
Stock Titan enhances these filings with AI-powered summaries that explain the main points of lengthy documents in plain language. Real-time updates from EDGAR, combined with AI-generated highlights of sections such as business descriptions, risk discussions, and capital market disclosures, help readers navigate Ping An Biomedical’s regulatory record more efficiently.
Ping An Biomedical Co., Ltd. (PASW) entered into a letter of intent on October 22, 2026, with Future Biotechnology Group Co., Limited for the planned acquisition of three tumor cell-related medical technology patents, for consideration ranging from US 2 million to US 2.5 million. The transaction is subject to due diligence, negotiation and execution of definitive agreements, and applicable regulatory and contractual requirements.
The patents cover oncology diagnosis and treatment, cell detection and bioengineering, and biomarker and DNA probe technologies. Upon completion, PASW intends to add them to its healthcare technology intellectual-property reserve and assess internal research and development, collaboration, or licensing pathways, subject to further assessment and applicable approvals. The company does not expect the acquisition, by itself, to generate material revenue in the near term.
Ping An Biomedical Co., Ltd. (PASW) filed a shelf registration for an aggregate amount of up to US$300,000,000 in Class A ordinary shares, preferred shares, debt securities, warrants, share purchase contracts, share purchase units, units and rights. Sales may occur from time to time after the registration statement becomes effective; a prospectus supplement will provide the terms of each offering.
While the market value of its Class A ordinary shares held by non-affiliates remains below $75,000,000, the company states that primary public sales under Form F-3 will not exceed one-third of that market value in any 12-month period. It reported approximately $6,851,487 in non-affiliate market value, based on 59.63 million shares held by non-affiliates and a $0.1149 closing price on October 8, 2026. The controlling shareholder, through Inspiretech Ltd, held approximately 91.56% of voting power as of the prospectus date. Ping An Biomedical is a Cayman Islands holding company that conducts its operations through its PRC subsidiary, and it does not expect to pay dividends on its Class A ordinary shares in the foreseeable future.
Ping An Biomedical Co., Ltd. (PASW) states that its 40-for-1 consolidation of issued and unissued Class A and Class B ordinary shares takes effect October 23, 2026; shareholders are scheduled to vote on ratifying it at an extraordinary general meeting on October 29. The consolidation changes authorized Class A shares from 4,900,000,000 to 122,500,000 and authorized Class B shares from 100,000,000 to 2,500,000, while authorized share capital remains US$312,500.
Other proposals would, subject to the specified approvals, increase authorized share capital to US$12,500,000, comprising 4,900,000,000 Class A and 100,000,000 Class B shares. Shareholders are also asked to approve further 10-for-1, 20-for-1, 50-for-1 or 80-for-1 consolidations if stated price and trading-day conditions occur. The September 29, 2026 record date determines voting eligibility; each ordinary share carries one vote.
Ping An Biomedical Co., Ltd. (PASW) will combine each 40 issued and unissued Class A and Class B ordinary shares into one share in a 1-for-40 reverse stock split effective October 23, 2026. As of October 21, 2026, the company had 112,867,000 Class A and 12,250,000 Class B shares issued and outstanding. It expects approximately 2,821,675 Class A and 306,250 Class B shares outstanding after the consolidation, subject to adjustment for fractional shares, which will be rounded up to the next whole share. Class A shares are expected to begin split-adjusted trading on the Nasdaq Capital Market at market open October 23 under PASW. Par value for each class will change from $0.0000625 to $0.0025 per share. The company says Cayman Islands counsel advised that the consolidation and its amended articles may need shareholder approval and ratification at a general meeting.
Ping An Biomedical Co., Ltd. (PASW) reported a sharp turnaround in profitability for the six months ended March 31, 2026. Revenue was RMB 9.59 million versus RMB 18.23 million a year earlier, but net income improved to RMB 4.83 million from a net loss of RMB 4.23 million, driven by a RMB 6.09 million reversal of credit losses and a RMB 5.67 million fair value gain on new equity investments. Earnings per share were RMB 0.10 versus a loss of RMB 0.24.
Total assets rose to RMB 100.22 million, including RMB 41.25 million of equity investments, while total shareholders’ equity increased to RMB 78.18 million. Working capital was RMB 33.87 million and operating cash flow was RMB 1.14 million. The company closed an IPO in July 2025 and subsequent private placements raising additional equity, and management states it expects existing resources to cover at least 12 months of operations, while acknowledging potential macro and demand uncertainties.
Ping An Biomedical Co., Ltd. reported a change in its independent auditors. On August 5, 2026, the board resolved not to reappoint WWC, P.C. as independent accountants, ending a relationship that began with the year ended September 30, 2020. WWC’s reports for the fiscal years ended September 30, 2024 and 2025 contained no adverse opinions or qualifications, and the company reports no disagreements or reportable events during WWC’s engagement.
The board approved the appointment of Edston Global PAC as the new independent registered public accounting firm, effective August 6, 2026. The company states it did not consult Edston on accounting principles, audit opinions, or any disagreements before this appointment. WWC’s confirming letter to the SEC, dated August 7, 2026, is included as an exhibit.
Ping An Biomedical Co., Ltd. reported that it has signed a strategic cooperation agreement with Yuan Sheng Mei Yan Health Services (Hainan) Co., Ltd., which will act as a channel development service provider. The partners share a goal of achieving cumulative sales of RMB 500 million within three years in the health and wellness services market.
Yuan Sheng Mei Yan will use its health management, wellness and government‑enterprise cooperation resources to expand channels and service scenarios, while Ping An Biomedical supplies biotechnology products and technical support. The company describes the cooperation as an important step in commercialization and channel development, aiming to broaden revenue sources and improve market penetration.
Ping An Biomedical Co., Ltd., through wholly owned subsidiary Meridian Industries Limited, entered into a sale and purchase deed with Multi Ridge (Asia) Limited dated July 2, 2026 covering certain trade mark and other IP rights in Hong Kong for USD2,500,000. Completion occurred on July 10, 2026, when legal and beneficial title to the IP rights passed, with an exclusive licence granted to the purchaser’s group pending local registrations.
The deed includes vendor and purchaser warranties and detailed claim mechanics. Claims, including warranty claims, generally require written notice and service of legal proceedings within 24 months after completion. The purchaser bears all stamp duty, filing, registration and similar taxes and indemnifies the vendor. The deed is governed by Hong Kong law with disputes subject to the exclusive jurisdiction of Hong Kong courts.
Ping An Biomedical Co., Ltd. has received an additional 180-day period from Nasdaq to regain compliance with its minimum bid price requirement. The company’s shares have been trading below the required $1 per share, breaching Nasdaq Listing Rule 5550(a)(2).
The new deadline to restore the bid price to at least $1 for 10 consecutive business days is November 23, 2026. Nasdaq granted the extension because the company meets other Capital Market listing standards, and the company indicated it may use a reverse stock split if needed.
The company is evaluating options and intends to regain compliance, but it cautions there is no assurance it will satisfy Nasdaq’s continued listing requirements.
Ping An Biomedical Co., Ltd. CEO Liu Pijun has filed an initial statement of beneficial ownership. The filing shows that 12,250,000 Class A Ordinary Shares are held indirectly through INSPIRETECH LTD, reflecting a substantial position associated with the chief executive but does not report any recent share purchases or sales.